Description
INDICATIONS
Chronic weight management:
Adults
Wegovy is indicated as an adjunct to a reduced-calorie diet and increased physical activity for weight management, including weight loss and weight maintenance, in adults with an initial Body Mass Index (BMI) of;
• ≥30 kg/m2 (obesity), or
• ≥27 kg/m2 to <30 kg/m2 (overweight) in the presence of at least one weight-related comorbidity.
Adolescents (≥12 years)
Wegovy is indicated as an adjunct to a reduced-calorie diet and increased physical activity for weight management in adolescents ages 12 years and above with;
• obesity and
• body weight above 60 kg.
Treatment with Wegovy should be discontinued and re-evaluated if adolescent patients have not reduced their BMI by at least 5% after 12 weeks on the 2.4 mg or maximum tolerated dose.
Obesity (BMI ≥95th percentile) as defined on sex- and age-specific BMI growth charts (CDC.gov).
Cardiovascular Risk Reduction:
Wegovy is indicated as an adjunct to a reduced-calorie diet and increased physical activity to reduce the risk of major adverse cardiovascular events (cardiovascular death, non-fatal myocardial infarction, or non-fatal stroke) in adults with established cardiovascular disease and either obesity or overweight (BMI ≥27 kg/m2).
DIRECTIONS FOR USE
Dosage:
Adults
The recommended dose is 2.4 mg once weekly. Your treatment will start at a low dose which will be gradually increased over 16 weeks of treatment as follows:
• When you first start using wegovy, the starting dose is 0.25 mg once weekly.
• Your doctor will instruct you to gradually increase your dose every 4 weeks until you reach the recommended dose of 2.4 mg once weekly.
• Once you reach the recommended dose of 2.4 mg, do not increase this dose further.
Titration schedule:
-
Week 1–4: 0.25 mg once weekly
-
Week 5–8: 0.5 mg once weekly
-
Week 9–12: 1 mg once weekly
-
Week 13–16: 1.7 mg once weekly
-
Week 17 onward: 2.4 mg once weekly (maintenance dose)
Adolescents
(above 12 years of age) For adolescents, the same dose escalation schedule as for adults should be applied (see above). The dose should be increased until 2.4 mg (maintenance dose) or maximum tolerated dose has been reached. Weekly doses higher than 2.4 mg are not recommended.
How to use:
wegovy is given as an injection under the skin (subcutaneous injection). Do not inject it into a vein or muscle.
• The best places to give the injection are the upper arms, stomach or upper legs.
• Before you use the pen for the first time, ask your doctor or nurse how to use it.
SIDE EFFECTS
Nausea, vomiting, diarrhea, constipation, abdominal pain, headache, fatigue, dizziness, burping, indigestion, bloating, decreased appetite, flatulence, injection site reactions, dehydration, gallstones, pancreatitis (rare), increased heart rate
PREGNANCY AND LACTATION
If you are pregnant or breast-feeding, think you may be pregnant or are planning to have a baby, ask your doctor for advice before taking this medicine.
ACTIVE INGREDIENTS
Semaglutide
